



Final Appraisal Recommendation

Advice No: 3013 – November 2013

Botulinum toxin type A (Botox[®]) 50 units, 100 units and 200 units powder for solution for injection

Submission by Allergan Ltd

Recommendation of AWMSG

Botulinum toxin type A (Botox[®]) is recommended as an option for use within NHS Wales for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1429), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Allergan Ltd
Date of first issue	November 2013
Last reviewed	December 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3013:
Botulinum toxin type A (Botox[®]) 50 units, 100 units and 200 units powder for solution for injection.
November 2013.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.